Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$2.36
-1.7%
$4.12
$7.96
$24.15
$11.90M0.6316,758 shs14,675 shs
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$6.55
+6.5%
$5.89
$4.35
$12.38
$309.15M0.43210,447 shs207,928 shs
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$7.84
+3.4%
$8.15
$6.85
$21.01
$447.33M-0.04529,346 shs333,400 shs
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
$0.36
$0.05
$11.78
$5.07M1.2434.54 million shs23.06 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
-1.67%-11.61%-15.41%-73.24%-86.84%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
+6.50%+5.99%+11.21%+9.35%-7.88%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
+3.43%-5.77%+0.38%-3.09%-54.86%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/AN/AN/AN/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
1.6329 of 5 stars
3.61.00.00.00.03.30.0
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
1.9091 of 5 stars
3.50.00.00.02.61.70.6
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00
N/AN/AN/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
3.25
Buy$22.00235.88% Upside
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3.00
Buy$30.00282.65% Upside
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CGEM, AURA, NSTG, and ALVR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$22.00
5/28/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$22.00
5/23/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$19.00
5/12/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $24.00
4/16/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
3/26/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$19.00
3/26/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
3/25/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$25.00
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/A$29.35 per shareN/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/A$3.04 per shareN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/A$10.14 per shareN/A
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
$127.26M0.00N/AN/A$0.98 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AlloVir, Inc. stock logo
ALVR
AlloVir
-$190.42M-$20.23N/AN/AN/A-71.03%-61.27%8/7/2025 (Estimated)
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$86.92M-$1.90N/AN/AN/AN/A-58.63%-49.74%8/14/2025 (Estimated)
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$167.38M-$2.91N/AN/AN/AN/A-29.47%-28.19%8/6/2025 (Estimated)
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
-$159.54M-$3.53N/AN/AN/A-102.44%-548.25%-53.79%N/A

Latest CGEM, AURA, NSTG, and ALVR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.47-$0.55-$0.08-$0.55N/AN/A
5/8/2025Q1 2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.78-$0.74+$0.04-$0.74N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/AN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/AN/A
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AlloVir, Inc. stock logo
ALVR
AlloVir
N/A
86.78
86.78
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/A
11.06
11.06
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/A
11.62
11.62
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/A
2.73
2.02

Institutional Ownership

CompanyInstitutional Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
66.05%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
96.75%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
86.31%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/A

Insider Ownership

CompanyInsider Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
32.07%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5.40%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
6.07%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
AlloVir, Inc. stock logo
ALVR
AlloVir
1105.04 million3.43 millionOptionable
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5050.27 million47.55 millionNot Optionable
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3059.01 million55.43 millionOptionable
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
55048.12 million46.63 millionOptionable

Recent News About These Companies

Bruker brokers $392M deal for frayed NanoString
NanoString Technologies Inc (NSTG)
Why Is NanoString (NSTG) Stock Up 115% Today?
NanoString Technologies, Inc. (NSTG)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AlloVir stock logo

AlloVir NASDAQ:ALVR

$2.36 -0.04 (-1.67%)
As of 06/23/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Aura Biosciences stock logo

Aura Biosciences NASDAQ:AURA

$6.55 +0.40 (+6.50%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$6.78 +0.23 (+3.44%)
As of 07:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Cullinan Therapeutics stock logo

Cullinan Therapeutics NASDAQ:CGEM

$7.84 +0.26 (+3.43%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$7.85 +0.01 (+0.11%)
As of 08:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

NanoString Technologies stock logo

NanoString Technologies NASDAQ:NSTG

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.